Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Upadacitinib

FDA-approved product (tablet, extended release, oral), marketed as Rinvoq, Rinvoq Lq.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Upadacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Upadacitinib. Its therapeutic class is shown instead.

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Upadacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Upadacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

    NCT07670156 · start 2026-10

    Registered record
    Registry ID
    NCT07670156
    Conditions
    JAK1 GOF; STAT1 GOF; STAT3 GOF; STAT5B GOF; STAT6 GOF
    Interventions
    Upadacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJAK1 GOF; STAT1 GOF; STAT3 GOF; STAT5B GOF +1 more
    InterventionUpadacitinib; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

    NCT07770646 · start 2026-09-14

    Registered record
    Registry ID
    NCT07770646
    Conditions
    Axial Spondyloarthritis (AxSpA)
    Interventions
    Secukinumab (IL-17i ); Upadacitinib (JAKi)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09-14
    Completion
    2029-09-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAxial Spondyloarthritis (AxSpA)
    InterventionSecukinumab (IL-17i ); Upadacitinib (JAKi)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

    NCT06016517 · start 2026-09-01

    Registered record
    Registry ID
    NCT06016517
    Conditions
    Arthritis, Rheumatoid
    Interventions
    Etanercept; Adalimumab; Upadacitinib; Tocilizumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-12-15
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionEtanercept; Adalimumab; Upadacitinib; Tocilizumab
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

    NCT07678645 · start 2026-06-01

    Registered record
    Registry ID
    NCT07678645
    Conditions
    Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Atopic Dermatitis (AD)
    Interventions
    Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2028-05-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Atopic Dermatitis (AD)
    InterventionUpadacitinib 15 MG
    PhasePhase 2
    Registry statusNot yet recruiting

  • Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）

    NCT07546097 · start 2026-03-23

    Registered record
    Registry ID
    NCT07546097
    Conditions
    Acute Severe Ulcerative Colitis
    Interventions
    Upadacitinib; Corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-23
    Completion
    2027-06-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Severe Ulcerative Colitis
    InterventionUpadacitinib; Corticosteroid
    PhasePhase 4
    Registry statusRecruiting

  • TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

    NCT07510191 · start 2026-03-01

    Registered record
    Registry ID
    NCT07510191
    Conditions
    Crohn Disease (CD)
    Interventions
    Upadacitinib; Infliximab Dose Intensification; Adalimumab Dose Intensification; Standard-Dose infliximab; Standard-Dose Adalimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2029-12-31
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn Disease (CD)
    InterventionUpadacitinib; Infliximab Dose Intensification; Adalimumab Dose Intensification; Standard-Dose infliximab +1 more
    PhasePhase 4
    Registry statusRecruiting

  • A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

    NCT07487311 · start 2026-01-07

    Registered record
    Registry ID
    NCT07487311
    Conditions
    Inflamatory Bowel Disease
    Interventions
    guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-01-07
    Completion
    2028-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflamatory Bowel Disease
    Interventionguselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib)
    PhaseNot recorded
    Registry statusRecruiting

  • Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

    NCT07138898 · start 2025-12-12

    Registered record
    Registry ID
    NCT07138898
    Conditions
    Rheumatic Disease
    Interventions
    Methotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide; Azathioprine; Mycophenolate; Cyclosporine; Tacrolimus; Etanercept; Adalimumab; Golimumab; Certolizumab; Infliximab; Rituximab; Belimumab; Tocilizumab; Anakinra; Canakinumab; Abatacept; Secukinumab; Ixekizumab; Bimekizumab; Ustekinumab; Guselkumab; Risankizumab; Tofacitinib; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-12
    Completion
    2028-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatic Disease
    InterventionMethotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide +23 more
    PhasePhase 2
    Registry statusRecruiting

  • Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

    NCT07149467 · start 2025-09-10

    Registered record
    Registry ID
    NCT07149467
    Conditions
    Crohn' s Disease Aggravated; Crohn' s Disease in Remission
    Interventions
    Ustekinumab (approximately 6 mg/kg); Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-09-10
    Completion
    2027-12-31
    Enrolment
    454

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn' s Disease Aggravated; Crohn' s Disease in Remission
    InterventionUstekinumab (approximately 6 mg/kg); Upadacitinib
    PhasePhase 3
    Registry statusNot yet recruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

    NCT07073079 · start 2025-07-14

    Registered record
    Registry ID
    NCT07073079
    Conditions
    Crohn's Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-14
    Completion
    2027-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

    NCT07008846 · start 2025-05-10

    Registered record
    Registry ID
    NCT07008846
    Conditions
    Moderate to Severe Rheumatoid Arthritis
    Interventions
    To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-05-10
    Completion
    2026-09-30
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Rheumatoid Arthritis
    InterventionTo see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis
    PhasePhase 3
    Registry statusActive not recruiting

  • Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

    NCT06862284 · start 2025-03-10

    Registered record
    Registry ID
    NCT06862284
    Conditions
    Primary Sjögren's Syndrome (pSS)
    Interventions
    Upadacitinib (ABT-494); Hydroxychloroquine (HCQ)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-03-10
    Completion
    2027-08-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Sjögren's Syndrome (pSS)
    InterventionUpadacitinib (ABT-494); Hydroxychloroquine (HCQ)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy of Upadacitinib After NECS in Vitiligo

    NCT06454461 · start 2024-12-04

    Registered record
    Registry ID
    NCT06454461
    Conditions
    Vitiligo
    Interventions
    Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-04
    Completion
    2029-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionUpadacitinib 15 MG
    PhaseNot applicable
    Registry statusRecruiting